Pharmacogenetics of thiazolidinedione therapy

被引：13

作者：

Aquilante, Christina L. ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA

来源：

PHARMACOGENOMICS | 2007年 / 8卷 / 08期

关键词：

pharmacoagenecics; pharmacogenomics; pioglitazone; rosightazone; thiazolidinedione; troglitazone;

D O I：

10.2217/14622416.8.8.917

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The thiazoliclinediones (TZDs) are peroxisome proliferator-activated receptor-gamma, agonists and have glucose-lowering, insulin-sensitizing and anti-inflammatory effects. TZDs are approved for the treatment of Type 2 diabetes, and have been studied as a diabetes-prevention strategy. Despite widespread use of TZDs, a large number of patients fail to achieve a substantial reduction in glucose, or an improvement in insulin sensitivity, following treatment. Available data suggest that polymorphisms in genes encoding TZD drug targets, effector proteins and metabolizing enzymes contribute to the observed interindividual variability in TZD response and disposition. The purpose of this review is to highlight recent developments in the field of TZD pharmacogenetics, specifically focusing on clinical studies that have investigated genetic determinants of TZD response (i.e., reduction in glycemia and improvement in insulin sensitivity), disposition (i.e., pharmacokinetics), and side effects in patients with Type 2 diabetes and patients at risk for Type 2 diabetes.

引用

页码：917 / 931

页数：15

共 89 条

[61] Plasma adiponectin levels and risk of myocardial infarction in men [J].

Pischon, T ;

Girman, CJ ;

Hotamisligil, GS ;

Rifai, N ;

Hu, FB ;

Rimm, EB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1730-1737

[62] A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis [J].

Promrat, K ;

Lutchman, G ;

Uwaifo, GI ;

Freedman, RJ ;

Soza, A ;

Heller, T ;

Doo, E ;

Ghany, M ;

Premkumar, A ;

Park, Y ;

Liang, TJ ;

Yanovski, JA ;

Kleiner, DE ;

Hoofnagle, JH .

HEPATOLOGY, 2004, 39 (01) :188-196

[63] Pharmacogenetic evidence that Cd36 is a key determinant of the metabolic effects of pioglitazone [J].

Qi, NN ;

Kazdova, L ;

Zidek, V ;

Landa, V ;

Kren, V ;

Pershadsingh, HA ;

St Lezin, E ;

Abumrad, NA ;

Pravenec, M ;

Kurtz, TW .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (50) :48501-48507

[64] Lipoprotein lipase S447X - A naturally occurring gain-of-function mutation [J].

Rip, Jaap ;

Nierman, Melchior C. ;

Ross, Colin J. ;

Jukema, Jan Wouter ;

Hayden, Michael R. ;

Kastelein, John J. P. ;

Stroes, Erik S. G. ;

Kuivenhoven, Jan Albert .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (06) :1236-1245

[65] Pharmacogenomics: Challenges and opportunities [J].

Roden, Dan M. ;

Altman, Russ B. ;

Benowitz, Neal L. ;

Flockhart, David A. ;

Giacomini, Kathleen M. ;

Johnson, Julie A. ;

Krauss, Ronald M. ;

McLeod, Howard L. ;

Ratain, Mark J. ;

Relling, Mary V. ;

Ring, Huijun Z. ;

Shuldiner, Alan R. ;

Weinshilboum, Richard M. ;

Weiss, Scott T. .

ANNALS OF INTERNAL MEDICINE, 2006, 145 (10) :749-757

[66] Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome [J].

Samaha, FF ;

Szapary, PO ;

Iqbal, N ;

Williams, MM ;

Bloedon, LT ;

Kochar, A ;

Wolfe, ML ;

Rader, DJ .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (03) :624-630

[67] THE EFFECT OF INTENSIVE TREATMENT OF DIABETES ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].

SHAMOON, H ;

DUFFY, H ;

FLEISCHER, N ;

ENGEL, S ;

SAENGER, P ;

STRELZYN, M ;

LITWAK, M ;

WYLIEROSETT, J ;

FARKASH, A ;

GEIGER, D ;

ENGEL, H ;

FLEISCHMAN, J ;

POMPI, D ;

GINSBERG, N ;

GLOVER, M ;

BRISMAN, M ;

WALKER, E ;

THOMASHUNIS, A ;

GONZALEZ, J ;

GENUTH, S ;

BROWN, E ;

DAHMS, W ;

PUGSLEY, P ;

MAYER, L ;

KERR, D ;

LANDAU, B ;

SINGERMAN, L ;

RICE, T ;

NOVAK, M ;

SMITHBREWER, S ;

MCCONNELL, J ;

DROTAR, D ;

WOODS, D ;

KATIRGI, B ;

LITVENE, M ;

BROWN, C ;

LUSK, M ;

CAMPBELL, R ;

LACKAYE, M ;

RICHARDSON, M ;

LEVY, B ;

CHANG, S ;

HEINHEINEMANN, M ;

BARRON, S ;

ASTOR, L ;

LEBECK, D ;

BRILLON, D ;

DIAMOND, B ;

VASILASDWOSKIN, A ;

LAURENZI, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :977-986

[68] Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional pro 12Ala peroxisome proliferator-activated receptor-γ2 gene variant -: Results from the Troglitazone in Prevention of Diabetes (TRIPOD) study [J].

Snitker, S ;

Watanabe, RM ;

Ani, I ;

Xiang, AH ;

Marroquin, A ;

Ochoa, C ;

Goico, J ;

Shuldiner, AR ;

Buchanan, TA .

DIABETES CARE, 2004, 27 (06) :1365-1368

[69] Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism [J].

Soyama, A ;

Saito, Y ;

Hanioka, N ;

Murayama, N ;

Nakajima, O ;

Katori, N ;

Ishida, S ;

Sai, K ;

Ozawa, S ;

Sawada, J .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2001, 24 (12) :1427-1430

[70] The peroxisome proliferator-activated receptor-γ2 pro12Ala polymorphism [J].

Stumvoll, M ;

Häring, H .

DIABETES, 2002, 51 (08) :2341-2347

← 1 2 3 4 5 6 7 8 9 →